100 related articles for article (PubMed ID: 22467923)
1. Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis.
Mesko B; Poliska S; Szamosi S; Szekanecz Z; Podani J; Varadi C; Guttman A; Nagy L
J Rheumatol; 2012 May; 39(5):916-28. PubMed ID: 22467923
[TBL] [Abstract][Full Text] [Related]
2. IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis.
Lundström SL; Hensvold AH; Rutishauser D; Klareskog L; Ytterberg AJ; Zubarev RA; Catrina AI
Arthritis Res Ther; 2017 Aug; 19(1):182. PubMed ID: 28793911
[TBL] [Abstract][Full Text] [Related]
3. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
Oliveira RD; Fontana V; Junta CM; Marques MM; Macedo C; Rassi DM; Passos GA; Donadi EA; Louzada-Junior P
J Rheumatol; 2012 Aug; 39(8):1524-32. PubMed ID: 22753658
[TBL] [Abstract][Full Text] [Related]
4. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray.
Sanayama Y; Ikeda K; Saito Y; Kagami S; Yamagata M; Furuta S; Kashiwakuma D; Iwamoto I; Umibe T; Nawata Y; Matsumura R; Sugiyama T; Sueishi M; Hiraguri M; Nonaka K; Ohara O; Nakajima H
Arthritis Rheumatol; 2014 Jun; 66(6):1421-31. PubMed ID: 24591094
[TBL] [Abstract][Full Text] [Related]
5. Changes of glycosylation of IgG in rheumatoid arthritis patients treated with methotrexate.
Gińdzieńska-Sieśkiewicz E; Radziejewska I; Domysławska I; Klimiuk PA; Sulik A; Rojewska J; Gabryel-Porowska H; Sierakowski S
Adv Med Sci; 2016 Sep; 61(2):193-197. PubMed ID: 26876088
[TBL] [Abstract][Full Text] [Related]
6. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment.
Collins ES; Galligan MC; Saldova R; Adamczyk B; Abrahams JL; Campbell MP; Ng CT; Veale DJ; Murphy TB; Rudd PM; Fitzgerald O
Rheumatology (Oxford); 2013 Sep; 52(9):1572-82. PubMed ID: 23681398
[TBL] [Abstract][Full Text] [Related]
7. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
[TBL] [Abstract][Full Text] [Related]
9. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.
Okano T; Inui K; Tada M; Sugioka Y; Mamoto K; Wakitani S; Koike T; Nakamura H
Rheumatol Int; 2016 Mar; 36(3):349-57. PubMed ID: 26438386
[TBL] [Abstract][Full Text] [Related]
10. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
11. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
12. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.
Julià A; Barceló M; Erra A; Palacio C; Marsal S
Pharmacogenomics; 2009 Oct; 10(10):1697-708. PubMed ID: 19842941
[TBL] [Abstract][Full Text] [Related]
13. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
[TBL] [Abstract][Full Text] [Related]
14. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment.
Roll P; Muhammad K; Schumann M; Kleinert S; Einsele H; Dörner T; Tony HP
Arthritis Rheum; 2011 May; 63(5):1255-64. PubMed ID: 21305508
[TBL] [Abstract][Full Text] [Related]
15. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
16. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial.
Sellam J; Marion-Thore S; Dumont F; Jacques S; Garchon HJ; Rouanet S; Taoufik Y; Hendel-Chavez H; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Chiocchia G
Arthritis Rheumatol; 2014 Aug; 66(8):2015-25. PubMed ID: 24756903
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
18. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P; Thompson E; Woodworth T; Smolen JS
Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
20. Galactosylation of IgG from rheumatoid arthritis (RA) patients--changes during therapy.
Pasek M; Duk M; Podbielska M; Sokolik R; Szechiński J; Lisowska E; Krotkiewski H
Glycoconj J; 2006 Nov; 23(7-8):463-71. PubMed ID: 17006638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
